Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;11(6):597-606.
doi: 10.1111/cts.12577. Epub 2018 Jul 30.

The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development

Tohru Takebe  1 , Ryoka Imai  2 , Shunsuke Ono  3
Affiliations

The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development

Tohru Takebe et al. Clin Transl Sci. 2018 Nov.

Abstract

Academic drug discovery is a vital component to current drug discovery and development environments. In this study, we investigated 798 drug discovery projects that took place between 1991 and 2015 at 36 academic institutions in the United States. The observed success rates of academic drug discovery and development were 75% at phase I, 50% at phase II, 59% at phase III, and 88% at the new drug application/biologics license application (NDA/BLA) phase. These results were similar to the corresponding success rates of the pharmaceutical industry. Collaboration between academic institutions and the pharmaceutical industry seemed more important at later stages than earlier ones; all projects that succeeded at phase III or the NDA/BLA stage involved academic-industrial collaboration. Many academic research projects involved neoplasms and infectious diseases, and were focused on small molecules and biologics. The success rates and possible effects of academic-industrial collaboration seemed to vary depending on disease domains and drug modalities.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phase success and likelihood of approvals (LOA) rates of academic drug discovery and development that was begun between 1991 and 2010. NDA/BLA, new drug application/biologics license application.
Figure 2
Figure 2
The impact of academic‐industrial collaboration on academic drug discovery and development projects that were begun between 1991 and 2010. NDA/BLA, new drug application/biologics license application; NR, not reportable.
Figure 3
Figure 3
The classifications of academic drug discovery projects that were begun between 1991 and 2010 by International Statistical Classification of Diseases and Related Health Problems 10th Revision.
Figure 4
Figure 4
The differences in success and collaboration rates for academic drug discovery and development projects that were begun between 1991 and 2010, presented by disease areas. NDA/BLA, new drug application/biologics license application.
Figure 5
Figure 5
The current status of modalities in academic drug discovery and development projects that were begun between 1991 and 2010. (a) Proportion of modalities in academic drug discovery (N = 798) (b) Proportion of modality by disease area in academic drug discovery.
Figure 6
Figure 6
Success and collaboration rates by modality in academic drug discovery and development projects. NDA/BLA, new drug application/biologics license application.
See this image and copyright information in PMC

References

    1. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959–968 (2009). - PubMed
    1. Mullard, A. 2012 FDA drug approvals. Nat. Rev. Drug Discov. 12, 87–90 (2013). - PubMed
    1. Hay, M. , Thomas, D.W. , Craighead, J.L. , Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40–51 (2014). - PubMed
    1. Biotechnology Innovation organization, Biomedtracker, Amplion Clinical Development Success Rates 2006‐2015 (BIO, Washington, DC, BioMedTracker, CA, Ampion, OR, 2016) <https://www.bio.org/sites/default/files/Clinical%20Development%20Success...>.
    1. Pharmaceutical Research and Manufacturers of America 2015 biopharmaceutical research industry profile. PhRMA, Washington, DC: (2015).

MeSH terms

LinkOut - more resources